PMID- 23974048
OWN - NLM
STAT- MEDLINE
DCOM- 20140602
LR  - 20131021
IS  - 1872-9754 (Electronic)
IS  - 0197-0186 (Linking)
VI  - 63
IP  - 5
DP  - 2013 Nov
TI  - Etazolate rescues behavioral deficits in chronic unpredictable mild stress model: 
      modulation of hypothalamic-pituitary-adrenal axis activity and brain-derived 
      neurotrophic factor level.
PG  - 465-75
LID - S0197-0186(13)00214-3 [pii]
LID - 10.1016/j.neuint.2013.08.005 [doi]
AB  - Preliminary study in our laboratory showed that etazolate produced 
      antidepressant- and anxiolytic-like effects in rodent models, however, the 
      ability of etazolate to produce antidepressant- and anxiolytic-like effects and 
      underlying mechanism(s) in chronic unpredictable mild stress (CUMS) model have 
      not been adequately addressed. This study was aimed to investigate the beneficial 
      effects of etazolate on CUMS-induced behavioral deficits (depression- and 
      anxiety-like behaviors). In addition, the possible underlying mechanism(s) of 
      etazolate in CUMS model was also investigated by measuring serum corticosterone 
      (CORT) and brain-derived neurotrophic factor (BDNF) levels. Mice were subjected 
      to a battery of stressors for 28 days. Etazolate (0.5 and 1 mg/kg, p.o.) and 
      fluoxetine (20mg/kg, p.o.) were administered during the last 21 days (8-28th) of 
      the CUMS paradigm. The results showed that 4-weeks CUMS produces significant 
      depression-like behavior in tail suspension test (TST) and partial anxiety-like 
      behavior in elevated plus maze (EPM) and open field test (OFT). Stressed mice 
      have also shown a significant high serum CORT and low BDNF level. Chronic 
      treatment with etazolate (0.5 and 1mg/kg., p.o.) and fluoxetine (20mg/kg., p.o.) 
      produced significant antidepressant-like behavior in TST (decreased duration of 
      immobility), whereas, partial anxiolytic-like behavior in EPM (increased 
      percentage of open arm entries) and OFT (increased % central ambulation score, 
      total ambulation score and time spent in center zone). In addition, etazolate and 
      fluoxetine treatment significantly (p<0.05) increased the BDNF level and 
      inhibited the hypothalamic-pituitary-adrenocortical (HPA) axis hyperactivity, as 
      evidenced by low serum CORT level in stressed mice. In addition, etazolate and 
      fluoxetine also showed significant antidepressant- and anxiolytic-like effects in 
      normal control mice. In this study no significant changes were observed in 
      locomotor activity in actophotometer test. Moreover, we did not find any effect 
      of etazolate and fluoxetine on CORT and BDNF levels in normal control mice. In 
      conclusion, the results of the present study suggested compelling evidences that 
      etazolate has more marked effect on depression-like behavior in mice, which is 
      atleast in part may be related to their modulating effects on the HPA axis and 
      BDNF level.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Jindal, Ankur
AU  - Jindal A
AD  - Department of Pharmacy, Birla Institute of Technology & Science, Pilani 333031, 
      Rajasthan, India. Electronic address: kumarjindal26@gmail.com.
FAU - Mahesh, Radhakrishnan
AU  - Mahesh R
FAU - Bhatt, Shvetank
AU  - Bhatt S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130822
PL  - England
TA  - Neurochem Int
JT  - Neurochemistry international
JID - 8006959
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - I89Y79062L (Etazolate)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Etazolate/*pharmacology
MH  - Hypothalamo-Hypophyseal System/*drug effects
MH  - Mice
MH  - Pituitary-Adrenal System/*drug effects
MH  - Stress, Physiological/*drug effects
OTO - NOTNLM
OT  - BDNF
OT  - CUMS
OT  - Depression
OT  - Etazolate
OT  - HPA axis
EDAT- 2013/08/27 06:00
MHDA- 2014/06/03 06:00
CRDT- 2013/08/27 06:00
PHST- 2013/03/19 00:00 [received]
PHST- 2013/07/28 00:00 [revised]
PHST- 2013/08/15 00:00 [accepted]
PHST- 2013/08/27 06:00 [entrez]
PHST- 2013/08/27 06:00 [pubmed]
PHST- 2014/06/03 06:00 [medline]
AID - S0197-0186(13)00214-3 [pii]
AID - 10.1016/j.neuint.2013.08.005 [doi]
PST - ppublish
SO  - Neurochem Int. 2013 Nov;63(5):465-75. doi: 10.1016/j.neuint.2013.08.005. Epub 
      2013 Aug 22.